Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Several other equities analysts also recently commented on KURA. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. StockNews.com upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, February 27th. Jefferies Financial Group dropped their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Bank of America dropped their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. Finally, TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $7.37 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company has a market cap of $573.12 million, a price-to-earnings ratio of -3.12 and a beta of 0.85. The stock has a fifty day moving average price of $8.07 and a 200-day moving average price of $13.56.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. As a group, equities analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last 90 days. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in KURA. Harbor Capital Advisors Inc. grew its stake in Kura Oncology by 21.9% in the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after acquiring an additional 8,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Kura Oncology by 35.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after purchasing an additional 7,722 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Kura Oncology in the third quarter valued at $298,000. Charles Schwab Investment Management Inc. grew its position in shares of Kura Oncology by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after purchasing an additional 14,106 shares in the last quarter. Finally, Algert Global LLC grew its position in shares of Kura Oncology by 4.4% in the third quarter. Algert Global LLC now owns 272,276 shares of the company’s stock valued at $5,320,000 after purchasing an additional 11,493 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.